Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis by Leonardi, C et al.
THERAPEUTICS DOI 10.1111/j.1365-2133.2008.08548.x
Efalizumab: results of a 3-year continuous dosing study for
the long-term control of psoriasis
C. Leonardi, A. Menter,* T. Hamilton,  I. Caro,  B. Xing  and A.B. Gottlieb§
Central Dermatology, Saint Louis University School of Medicine, St Louis, MO 63117, U.S.A.
*Baylor Research Institute, Dallas, TX, U.S.A.
 Atlanta Dermatology, Vein & Research Center, LLC, Alpharetta, GA, U.S.A.
 Genentech, Inc., South San Francisco, CA, U.S.A.
§Department of Dermatology, Tufts–New England Medical Center, Boston, MA, U.S.A.
OnlineOpen:This article is available free online at www.blackwell-synergy.com             
Correspondence
Craig Leonardi.
E-mail: leonardi@centralderm.com
Accepted for publication
5 January 2008
Key words
efalizumab, heavy patient response,
immunosuppressant, monoclonal antibody, plaque
psoriasis, T-cell modulation
Conﬂicts of interest
C.L. with 3M Pharmaceuticals, Abbott, Allergan,
Altana, Amgen, Astellas-Biogen, Bri0stol Myers,
Centocor, CombinatoRx, Fujisawa Healthcare,
Galderma, Genentech, Merck Serono International
SA, Schering Plough, RTL, Vitae and Warner
Chilcott; A.M. with 3M Pharmaceuticals, Abbott,
Allergan, Allermed, Amgen, Astralis, Berlex,
Biogen Idec, Celgene, Centocor, Cephalon,
Collagenex Pharmaceuticals, CombinatoRx,
Connetics, Corixa, Dermik Laboratories, Doak
Dermatologics, Dow, Ferndale Laboratories,
Fujisawa Healthcare, Galderma, Genentech,
Genzyme, GlaxoSmithKline, Ligand
Pharmaceuticals, Medicis, MedImmune, Novartis
Pharmaceuticals, Otsuka Pharmaceutical, Protein
Design Labs, QLT USA, Regeneration Pharma AG,
Roche, Merck Serono International SA, Sinclair,
Synta Pharma, Thermosurgery, Vertex, Warner
Chilcott, Wyeth, XOMA and Zars; T.H. with
Genentech; A.B.G. with Abbott, Actelion,
Almirall, Amgen, Beiersdorf, Biogen Idec, Bristol
Myers Squibb, Can-Fite, Celera, Celgene,
Centocor, DermiPsor, Eisai, Genentech, Immune
Control, Incyte, Kemia, Medacorp, Medarex, Novo
Nordisk, Pharmacare, Roche, RxClinical, Sankyo,
Schering Plough, TEVA, UCB, Warner Chilcott
and Wyeth. All income derived from these sources
goes to her employer. I.C. and B.X. are employees
and stockholders of Genentech.
Re-use of this article is permitted in accordance
with the Creative Commons Deed, Attribution
2Æ5, which does not permit commercial
exploitation.
Summary
Background Efalizumab, a T-cell-targeted, recombinant, humanized, monoclonal
IgG1 antibody, inhibits key T-cell-mediated steps in the pathogenesis of psoriasis.
Efalizumab is approved for the treatment of moderate-to-severe chronic plaque
psoriasis in adults in more than 50 countries.
Objectives To evaluate the efﬁcacy and safety of long-term, continuous efalizumab
therapy in patients with psoriasis.
Methods This open-label, multicentre phase III study enrolled 339 patients with
moderate-to-severe chronic plaque psoriasis. During the initial 3-month phase,
patients received subcutaneous efalizumab 2 mg kg
)1 weekly with randomization
to receive concomitant ﬂuocinolone acetonide or placebo ointment during month
3. The second phase was a long-term observational period; patients achieving a
‡ 50% improvement in the Psoriasis Area and Severity Index (PASI) score were
eligible to receive efalizumab 1 mg kg
)1 weekly for up to 33 months. The
ﬁnal 3-month treatment period was an optional transition period for patients
who completed the 33-month segment before efalizumab became commercially
available.
Results After 3 months, 41Æ3% of patients achieved a ‡ 75% improvement in PASI
(PASI-75) and 13Æ0% achieved a ‡ 90% improvement (PASI-90). Continued
improvement was observed: 45Æ4% and 24Æ5% achieved PASI-75 and PASI-90,
respectively, at the end of the observational phase. The safety proﬁle was
stable, with no new or no increase in common events over 36 months of
treatment.
Conclusions This was the longest continuous study using a biologic therapy for pso-
riasis. Clinical beneﬁt of efalizumab improved over the ﬁrst 18 months and was
maintained during 36 months of continuous therapy. Long-term efalizumab ther-
apy is appropriate for many patients with plaque psoriasis.
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treatment for symptom control.
1 Systemic therapies, such as
methotrexate, ciclosporin, retinoids, corticosteroids and photo-
therapy, are traditionally used to treat patients with moderate-
to-severe disease. However, the long-term use of these therapies
may be limited by inconvenience (phototherapy) or increased
toxicities,
2 which may include liver and bone marrow toxicity
for methotrexate,
3,4 renal toxicity and hypertension for
ciclosporin,
5,6 teratogenicity for retinoids,
4,7 and an increased
risk of skin cancer for phototherapy.
8 Rotational, combination
and sequential treatment strategies are employed to reduce
toxicity, leading to cycles of disease remission and relapse, with
a negative impact on patients’ quality of life.
3,9–11 Efalizumab is
a recombinant humanized monoclonal IgG1 antibody that
targets key T-cell-mediated steps in the immunopathogenesis of
psoriasis.
12 Multiple clinical trials of 12–24 weeks’ duration
have demonstrated the efﬁcacy and safety proﬁle of efalizumab
and led to its approval in more than 50 countries for the
treatment of adult patients with moderate-to-severe chronic
plaque psoriasis.
13–17
Psoriasis is a chronic disease requiring long-term therapy. A
placebo-controlled study of this length would raise ethical and
retention concerns. The use of a systemic comparator arm
(e.g. ciclosporin or methotrexate) for this length of time is
also problematic because of cumulative toxicity and blind-
ing. This 36-month (3-year) continuous dosing study of
efalizumab is the longest prospective study of a biologic
therapy in psoriasis to date.
Materials and methods
Study design
This was an open-label, multicentre, phase III clinical study.
Details of the study design have also been previously
described
18,19 (Fig. 1). Patients were adults (aged ‡ 18 years)
with a diagnosis of psoriasis for ‡ 6 months, with a Psoriasis
Area and Severity Index (PASI) score ‡ 12 and psoriasis cover-
ing ‡ 10% of body surface area (BSA), who were candidates
for systemic therapy. All investigator sites received Institutional
Review Board approval prior to initiating the study, and all
patients provided signed informed consent.
The aims of the study were to evaluate the duration of
response and the effectiveness of prolonged maintenance ther-
apy as reﬂected by the PASI score during long-term treatment
with efalizumab. Previous clinical studies have indicated that
some patients respond with relatively long-lasting residual ery-
thema in sites of resolving plaque psoriasis during efalizumab
treatment. To address the erythema, topical therapy was intro-
duced during the third month of treatment after efalizumab
typically had effected an improvement in total disease burden.
Thus, an early endpoint of this study was a comparison of the
efﬁcacy of 12 weekly injections of efalizumab with and with-
out concomitant administration of topical corticosteroid oint-
ment added during the third month of the treatment period.
During the ﬁrst 3 months (12 weeks), the initial phase of
the study, patients received subcutaneous (SC) efalizumab
2m gk g
)1 weekly. To address the concern that persistent ery-
thema would inﬂuence PASI responses and hinder patient
entry to the second phase of the study, the effect of concomi-
tant use of a weak topical steroid was investigated during
month 3. Patients were randomized to receive concomitant
ﬂuocinolone acetonide ointment 0Æ025% (n = 169) or placebo
equivalent (white petrolatum ointment; n = 170) during
weeks 9–12, as described previously.
18 The second phase of
the study was a long-term observational period in which after
3 months, patients who achieved a ‡ 50% improvement in
PASI relative to baseline (PASI-50) or a static Physician’s Glo-
bal Assessment (sPGA) rating of mild, minimal or clear on the
Overall Lesion Severity (OLS) scale were eligible for an add-
itional period of up to 12 months of maintenance therapy in
3-month segments with SC efalizumab 1 mg kg
)1 weekly.
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Fig 1. Study design. *All patients continued to receive efalizumab during weeks 9–12; patients were also randomized to receive either topical
placebo or topical steroid; the ﬁnal efalizumab dose in this 3-month (12-week) ﬁrst treatment period was administered at week 11.  Through
month 15, patients who relapsed ended participation in the current 3-month segment and started the next segment at 2 mg kg
)1 weekly with an
option to increase to maximum dosage of 4 mg kg
)1 weekly for up to 4 weeks following relapse. After month 15, no increase in dose was
permitted.  Patients who achieved a ‡ 50% improvement in the Psoriasis Area and Severity Index score or static Physician’s Global Assessment of
mild, minimal or clear at the end of the ﬁrst treatment period were eligible to enter the maintenance treatment period. §The optional transition
period was made available to patients who had completed 33 months of efalizumab therapy prior to the availability of commercial drug. Other
patients transitioned to commercial efalizumab after month 33.
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eﬁt were withdrawn from the study. Subsequent amendments
to the protocol extended the study so that patients were eligi-
ble for up to a total of 33 months of therapy. If patients expe-
rienced a protocol-deﬁned relapse (loss of ‡ 50% of the PASI
improvement achieved between baseline and week 12) during
months 4–15, they immediately ended participation in their
current 3-month segment and started their next segment at an
escalated dosage of 2 mg kg
)1 weekly. At the investigator’s
discretion, efalizumab could be escalated up to 4 mg kg
)1
weekly. In total, 25 patients were treated with an escalated
dose of 3 mg kg
)1 weekly (n = 10) for a median duration of
4 weeks (range 2–55) or 4 mg kg
)1 weekly (n = 15) for a
median duration of 4 weeks (range 2–21). However, dose
escalation was not permitted after month 15 per protocol.
Subsequent analysis of data from multiple clinical trials con-
ﬁrmed the dosage of 1 mg kg
)1 weekly as the appropriate
regimen for further studies in psoriasis.
13,14,20 The ﬁnal
3-month treatment segment (months 34–36) was a transition
period to bridge eligible patients from the study to commer-
cial efalizumab or another appropriate therapy, depending
upon the patient’s date of completion of month 33 relative to
the availability of commercial drug.
Better to reﬂect treatment patterns in clinical practice,
selected concomitant psoriasis medications were allowed dur-
ing the maintenance and transition treatment periods, includ-
ing emollients, scalp preparations, topical therapies, or
ultraviolet (UV) B phototherapy. All systemic psoriasis thera-
pies were excluded 1 month prior to the ﬁrst dose of
efalizumab and throughout the study.
Efﬁcacy assessment and analysis
The study was divided into 3-month (12-week) segments,
and PASI responses were evaluated at month 3 on the last day
of each treatment segment. The intent-to-treat (ITT) analysis
involved all 339 patients who entered into the study. Patients
who discontinued treatment during the ﬁrst treatment period
(months 0–3) were classiﬁed as nonresponders, and patients
who did not achieve a PASI-50 or an sPGA score of mild,
minimal or clear within the ﬁrst treatment period were dis-
continued from the study and considered nonresponders for
the remainder of the study. If a patient discontinued during
the maintenance treatment period (months 4–33), his or her
last PASI score was carried forward for each successive time
point (last observation carried forward, LOCF). Patients who
received an excluded systemic psoriasis therapy for a psoriasis
indication were considered nonresponders for the segment in
which they ﬁrst received the excluded medication and in all
subsequent segments. Patients who received a systemic psoria-
sis medication for an indication other than psoriasis had their
last PASI score prior to the segment in which they ﬁrst used
the systemic therapy carried forward for all subsequent seg-
ments (LOCF).
Secondary to the ITT analysis, an as-treated analysis
included only those patients who remained in the study and
initiated each treatment segment. Although not as conservative
as the ITT–LOCF analysis method, as-treated analysis is reﬂec-
tive of the efﬁcacy seen in the patients who persist on therapy
over time.
In a separate ITT analysis of patients by weight, patients
were divided into two groups, heavy (‡ 91 kg, n = 173) and
nonheavy (< 91 kg, n = 166) patients, and the analysis was
performed on each weight group with LOCF for missing
values.
As is common in long-term studies, this study had a num-
ber of patient discontinuations. Given that there is currently
no universally applicable method for handling missing values
[as recognized by International Conference on Harmonisation
(ICH) guidelines and the Committee for Proprietary Medicinal
Products (CPMP)],
21,22 the effect of continuous efalizumab
therapy on PASI score was analysed using two methodologies
(as-treated and ITT) to provide a reliable range of estimates of
efﬁcacy.
Safety assessment and analysis
To evaluate safety, the incidence of adverse events was analy-
sed during each 3-month treatment segment. Coding Symbols
for Thesaurus of Adverse Reaction Terms (COSTART) deﬁni-
tions were used. Safety assessments were conducted using the
as-treated population. All patients who received a concomitant
systemic medication were included in the safety analyses,
regardless of the indication.
Role of the funding source
Genentech, Inc. participated in study design, data collection
and data analysis; and Genentech, Inc. and Merck Serono
International SA participated in the writing of this report. The
corresponding author had full access to all the data in the
study and had ﬁnal responsibility for the decision to submit
for publication.
Results
Baseline characteristics
A total of 339 patients with moderate-to-severe psoriasis
at baseline enrolled in the study. The ﬁrst patient enrolled
on 2 February 2001, and the last patient enrolled on 18 July
2001. The patient population exhibited a median PASI score
of 17Æ2 (mean ± SD 19Æ8±8 Æ3) with a median BSA of
25Æ0% (mean ± SD 31Æ5±1 8 Æ5) and a median duration
of 16Æ0 years (mean ± SD 17Æ9±1 0 Æ6). Patient demogra-
phics and detailed baseline characteristics have been reported
previously.
18,19
Patient disposition
The 3-month ﬁrst treatment period was completed by 308
patients (90Æ9%), and 290 (85Æ5%) patients qualiﬁed for and
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of 146 patients (43Æ1%) completed the maintenance treatment
period and received 33 months of continuous efalizumab ther-
apy; 113 patients (33Æ3%) qualiﬁed for and entered the subse-
quent 3-month transition treatment period; and 108 patients
(31Æ9%) received a total of 36 months of efalizumab therapy
during the study. The rate of withdrawal during each 3-month
segment between month 3 and month 30 ranged from 4Æ0%
to 11Æ4%.
A total of 231 patients did not complete 36 months of
treatment; of these, 33 patients completed 33 months of
treatment and were discontinued for administrative reasons
(i.e. eligibility for transition to commercial efalizumab or
another appropriate therapy at end of study). Of the 198
other patients who discontinued from the study, 61 (30Æ8%)
did so for lack of efﬁcacy, with 17 of these discontinuing at
month 3 per protocol. Other reasons for discontinuation
were adverse events (47 patients; 23Æ7%), unknown reasons
(22 patients; 11Æ1%), loss to follow-up (20 patients; 10Æ1%),
and noncompliance, initiation of excluded therapy, preg-
nancy, withdrawal of consent, relocation or other reasons
(48 patients; 24Æ3%).
Use of concomitant medication
A total of 64 (18Æ9%) patients received an excluded systemic
therapy that could have affected the patient’s psoriasis
(Table 1). The majority of these cases involved nonpsoriasis
indications; 23 of the patients received concomitant medica-
tion for events classiﬁed as ‘joint pain’, which included psori-
atic arthritis, arthritis, osteoarthritis, gout, knee swelling,
tendonitis, bursitis, or pain in the temporomandibular joint,
foot, arm or ankle. Most patients who received disallowed sys-
temic therapies were discontinued from the study per study
protocol, including 15 patients who received disallowed con-
comitant medication for joint pain. For efﬁcacy analyses, any
such patient remaining in the study was treated using LOCF,
taking the last PASI score prior to use of the concomitant sys-
temic therapy. Patients who received an excluded systemic
therapy for an indication of psoriasis were included in the
efﬁcacy analysis only until the segment in which they ﬁrst
received the excluded medication. These patients were consid-
ered nonresponders in that and all subsequent treatment seg-
ments. Patients who received a systemic medication for an
indication other than psoriasis were evaluated using LOCF,
Fig 2. Patient disposition. *Patients were
categorized as discontinued only if they
withdrew from the study and did not enter
follow-up or discontinued from the study
segment and entered the follow-up.  Patients
who achieved a ‡ 50% improvement in the
Psoriasis Area and Severity Index score or
static Physician’s Global Assessment of mild,
minimal or clear at the end of the ﬁrst
treatment period were eligible to enter the
maintenance treatment period.  Patients who
relapsed during months 4–15 ended
participation in the current 3-month segment
and immediately started the next segment at
2–4 mg kg
)1 weekly. After month 15, no
further dose escalation was permitted. §The
optional transition period was made available
to patients who had completed 33 months of
efalizumab therapy prior to the availability of
commercial drug. Other patients transitioned
to commercial efalizumab after month 33.
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temic therapy for all subsequent segments.
During the study, 10 of 339 patients (2Æ9%) received a
concomitant systemic agent for psoriasis: six patients used
these for up to 3 months, and four patients used these for
up to 6 months. Eight of 10 uses of these agents were during
the maintenance period. For efﬁcacy analyses, these patients
were treated as nonresponders in all segments beginning with
the segment in which the patient received the concomitant
treatment.
Efﬁcacy
The ITT analysis demonstrates the maintenance of efalizumab
efﬁcacy throughout 36 months of continuous treatment
(Figs 3, 4). As previously reported, after the ﬁrst 3 months of
therapy 82Æ0% of all patients (n = 339) had achieved PASI-50,
41Æ3% had achieved a ‡ 75% improvement in PASI relative
to baseline (PASI-75), and 13Æ0% had achieved a ‡ 90%
improvement in PASI relative to baseline (PASI-90); and
76Æ1% had received an sPGA rating of mild or better on the
OLS scale.
18 Use of concomitant topical treatment during
month 3 demonstrated no signiﬁcant effect on PASI score,
with 42Æ0% and 40Æ6% of all patients achieving PASI-75 with
ﬂuocinolone acetonide ointment or placebo, respectively
(P =0 Æ826; Fig. 5a). After completion of the maintenance
treatment period (month 33), response rates for the ITT
population were 47Æ2% PASI-75 and 26Æ8% PASI-90. After
completion of the transition treatment period (month 36), the
response rates were 45Æ4% PASI-75 and 24Æ5% PASI-90.
Of the 25 patients receiving an escalated dose (3 mg kg
)1
weekly, n = 10; 4 mg kg
)1 weekly, n = 15), PASI-75 was
achieved by three patients (two receiving 3 mg kg
)1 weekly
and one receiving 4 mg kg
)1 weekly).
To assess the effect of concomitant phototherapy on
response, a retrospective analysis was performed excluding
patients who had used UVB phototherapy. Permitted UVB
phototherapy was used by 21 (6Æ2%) patients during the
study (Fig. 5b). In the subanalysis (performed as an ITT analy-
sis with patients using UVB considered as nonresponders),
PASI-75 was achieved by 40Æ7% and 43Æ1% of patients at 3
and 36 months, respectively, compared with 41Æ3% and
45Æ4% achieved by the total population at 3 and 36 months,
respectively.
Using the as-treated analysis, after completion of the main-
tenance treatment period (month 33), response rates were
74Æ8% PASI-75 (Fig. 4) and 41Æ1% PASI-90 (n = 151)
(Fig. 3). After completion of the transition treatment period
(month 36), the response rates were 72Æ6% PASI-75 and
39Æ8% PASI-90 (n = 113). PASI-50 at 33 and 36 months was
94Æ0%.
Table 1 Use of excluded concomitant systemic therapies and
permitted phototherapies (intent-to-treat population; n = 339)
Therapy
Number
treated at
any time, n
Indicated for
psoriasis, n (%)
Systemic therapy
a
Ciclosporin 1 1 (0Æ3)
Methotrexate 7 2 (0Æ6)
Systemic retinoids
b 66 ( 1 Æ8)
Biologics
c 30
Systemic corticosteroids
d 54 2 (0Æ6)
Other systemics 2 0
Total number of patients 64 10 (2Æ9)
Phototherapy
e 21 21 (6Æ2)
aNone of the systemic therapies listed was permitted per proto-
col; phototherapy was permitted.
bBexarotene and acitretin.
cEtanercept.
dCortisone acetate, dexamethasone, methylpredniso-
lone, prednisolone, prednisone, triamcinolone.
ePhototherapy
includes ultraviolet B and Not Otherwise Speciﬁed.
0 
20 
40 
60 
80 
100 
0  3  6  9  12 15 18 21 24 27 30 33 36 
ITT (n = 339) 
As-treated, n varies as shown
(n = 339)  (n = 339)  (n = 290)  (n = 269)  (n = 247)  (n = 228)  (n = 202)  (n = 194)  (n = 182)  (n = 170)  (n = 159)  (n = 151)  (n = 113) 
Months of efalizumab treatment 
P
a
t
i
e
n
t
s
 
a
c
h
i
e
v
i
n
g
 
P
A
S
I
-
9
0
 
(
%
)
 
Fig 3. PASI-90 (‡ 90% improvement in the Psoriasis Area and
Severity Index score) responses with 95% conﬁdence intervals for the
intent-to-treat (ITT) population (n = 339) and as-treated population
(n values listed below axis).
0 
20 
40 
60 
80 
100 
0  3  6  9  12 15 18 21 24 27 30 33 36 
ITT (n = 339) 
As-treated, n varies as shown
(n = 339)  (n = 339)  (n = 290)  (n = 269)  (n = 247)  (n = 228)  (n = 202)  (n = 194)  (n = 182)  (n = 170)  (n = 159)  (n = 151)  (n = 113) 
Months of efalizumab treatment 
P
a
t
i
e
n
t
s
 
a
c
h
i
e
v
i
n
g
 
P
A
S
I
-
7
5
 
(
%
)
Fig 4. PASI-75 (‡ 75% improvement in the Psoriasis Area and
Severity Index score) responses with 95% conﬁdence intervals for the
intent-to-treat (ITT) population (n = 339) and as-treated population
(n values listed below axis).
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uous efalizumab treatment is further illustrated by percentage
PASI improvement from baseline: ITT analysis demonstrated a
mean improvement of 63Æ8% by 3 months, a ﬁgure that
remained stable through 36 months (Fig. 6).
Efalizumab was administered to patients in a weight-
based dosage throughout the study. The treatment response
to efalizumab was maintained for heavy (‡ 91 kg; n = 173)
and nonheavy (< 91 kg; n = 166) patients over the
36-month period (Fig. 7). At 3 months, 39% and 42%
of heavy and nonheavy patients, respectively, achieved a
PASI-75 response to efalizumab; at 36 months, 46Æ2% and
44Æ6%, respectively, achieved PASI-75. Statistical analysis
at each point conﬁrmed that the two groups responded
similarly.
Safety and tolerability
Efalizumab was generally well tolerated throughout
36 months of continuous treatment, with no evidence of
cumulative or end-organ toxicity. Common adverse events
(‡ 5% of patients in any 3-month segment) during long-
term treatment included increased cough, rhinitis, sinusitis,
and nonspeciﬁc infection (e.g. colds). There was no increase
over time in the rate of those common adverse events. Like-
wise, no novel adverse events or increase in the overall inci-
dence of adverse events was noted over time. A low
proportion of patients (£ 3Æ1%) withdrew due to an adverse
event during each 3-month treatment segment of the mainte-
nance period.
Infection
The 30Æ2% incidence of infection-related adverse events
(adverse events that were diagnoses of infection or strongly
suggestive of infection) during the ﬁrst 3-month treatment
segment was comparable with that observed during previ-
ously reported 3-month placebo-controlled efalizumab clinical
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14,15,23 and did not increase over the course of the study
(Fig. 8a).
Malignancy
Malignancy rates were low and stable throughout the study
(Fig. 8b, Table 2). Most malignancies reported during the study
were nonmelanoma skin cancers (NMSCs) (22 events in 11
patients), with prior phototherapy [psoralen + UVA (PUVA)
and⁄or UVB] or extensive sun exposure being reported by eight
of these patients. Lymphoma was noted in two patients (one
after 24 months and one after 30 months of treatment), gastro-
intestinal carcinoma in two patients (one after 12 months and
one after 30 months of treatment), lung carcinoma in one
patient after 24 months of treatment, prostatic carcinoma in
one patient after 27 months of treatment, and cutaneous mela-
noma in situ in one patient after 6 months of treatment.
Psoriasis-related adverse events
Psoriasis-related adverse events were noted in 14 of 339 (4Æ1%)
patients in the ﬁrst 3-month segment, and in seven of 290
(2Æ4%) patients during the second 3-month segment (Fig. 8c).
Eight of 14 patients and seven of seven patients during the ﬁrst
and second 3-month segments, respectively, experienced a
recurrence of mild or moderate plaque psoriasis. However,
throughout the 36-month study, events of psoriasis ﬂare with
atypical papular or plaque lesions (n = 5), psoriatic erythroder-
ma (n = 3), inverse psoriasis (n = 2), guttate psoriasis (n =2 )
and pustular psoriasis (n = 1) were also reported. The incidence
of patients experiencing these events decreased to less than 1%
over the course of the 36 months of the study.
Arthritis
Arthritis-related adverse events, including events of arthritis,
psoriatic arthritis and osteoarthritis, were experienced by 45
patients over the 36-month period of the study; 16 of these
patients reported new onset of psoriatic arthritis. Eighteen of
the 45 patients withdrew from the study, including 15
patients who were treated with disallowed systemic agents for
management of their arthritis symptoms. The arthritis symp-
toms of the remaining 27 patients were managed with non-
steroidal anti-inﬂammatory drugs. Six patients (1Æ8%)
experienced a serious arthritis adverse event during the study:
three events were observed during the ﬁrst 3-month treatment
segment, and the other three events occurred during the sub-
sequent 33 months (Fig. 8c).
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Fig 8. Incidence of selected adverse events (AEs) reported for each
3-month exposure period over 36 months of continuous therapy.
Percentages are based on the number of patients and events in
each 3-month segment. The graphs show percentages of patients
who experienced at least one AE of the type speciﬁed during any
3-month period; multiple occurrences of the same event for a
patient were counted once in the overall incidence. (a) Infection-
related AEs ⁄infections (nonspeciﬁc). The shaded region indicates
the range of infection-related AEs observed for patients receiving
placebo for 3 months in controlled studies. (b) Serious
AEs ⁄malignancies. (c) Psoriasis-related AEs and arthritis-related AEs.
 Infection-related AEs include AEs that were diagnoses of infection
or strongly suggestive of infection.  Nonspeciﬁc infections, mostly
upper respiratory tract infections (e.g. bronchitis, pharyngitis,
rhinitis and sinusitis), were a subset of infection-related AEs. §Skin
cancer: a subset of serious AEs.
Table 2 Malignancies reported by study segment
Segment
of study Type of malignancy
Events
reported (n)
4–6 months Nonmelanoma skin carcinoma 1
7–9 months Nonmelanoma skin carcinoma 1
Malignant melanoma 1
10–12 months Nonmelanoma skin carcinoma 3
13–15 months Nonmelanoma skin carcinoma 1
Gastrointestinal carcinoma 1
16–18 months Nonmelanoma skin carcinoma 2
19–21 months Nonmelanoma skin carcinoma 2
22–24 months Nonmelanoma skin carcinoma 7
25–27 months Lymphoma-like reaction 1
Carcinoma of lung 1
Nonmelanoma skin carcinoma 1
28–30 months Nonmelanoma skin carcinoma 2
Prostatic carcinoma 1
31–33 months Lymphoma-like reaction 1
Gastrointestinal carcinoma 1
Nonmelanoma skin carcinoma 2
Total, 0–36
months
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There were 13 anaemia-related adverse events, all nonserious,
reported in seven patients: eight events of anaemia in six
patients, one event of iron-deﬁciency anaemia in one patient,
and four events of hypochromic anaemia in two patients.
There were no incidences of haemolytic anaemia. Six adverse
events of thrombocytopenia were reported in ﬁve patients,
three of whom were discontinued. Two of the events were
considered serious. One patient developed a serious event of
thrombocytopenia approximately 17 months after initiating
efalizumab. He was hospitalized for dehydration with a plate-
let count of 33 · 10
9 L
)1 and treated with prednisone; 7 days
later his count was 106 · 10
9 L
)1. Prednisone was tapered
and the patient was discontinued from the study. The second
patient developed a serious event of thrombocytopenia after
approximately 33 months of treatment with efalizumab. The
platelet count at presentation was 16 · 10
9 L
)1; dexametha-
sone was prescribed for 5 days and the patient was removed
from the study. The event resolved with a rapid recovery of
the patient’s platelet count. One patient experienced two mild
events of thrombocytopenia and was removed from the study
after the second event with a platelet count of 80 · 10
9 L
)1.
This patient had a platelet level below the normal range
(< 130 · 10
9 L
)1) at screening and throughout the study.
One patient developed congestive heart failure in the 31–
33-month segment of the study, an event deemed unrelated
to the study drug by the investigator.
The rate of withdrawal for any reason during each 3-month
segment between month 3 and month 30 was low, ranging
between 4Æ0% and 11Æ4%. This rate is similar to that observed
in other efalizumab studies with 3-month, placebo-controlled
treatment periods.
13,14
Discussion
This report presents ﬁnal results from the longest continuous-
treatment prospective study of a biologic therapy for psoriasis.
Clinical improvements, as measured by PASI-75 response rates
observed after the ﬁrst 3 months of efalizumab therapy in
patients with moderate-to-severe chronic plaque psoriasis,
were maintained throughout 36 months of continuous dosing.
The use of concomitant UVB phototherapy or topical treat-
ment had no additive effect on the outcome of response in
these patients.
For long-term studies, ITT analysis underestimates the actual
beneﬁt; thus, we have conducted an additional as-treated anal-
ysis as recommended in the revised Consolidated Standards of
Reporting Clinical Trials (CONSORT) statement.
24 This add-
itional analysis is intended to complement the primary ITT
analysis and to address the lack of any globally applicable
means of handling missing values, as recognized by the ICH
and CPMP.
21 As-treated analysis considers only the patients
who remain on therapy and does not take into consideration
those who discontinued treatment due to an adverse event,
lack of efﬁcacy or any other reasons.
During the ﬁrst 3 months of the study, 14Æ5% of the
patients discontinued; this rate included patients who did not
meet the eligibility criteria to continue and were forced to
withdraw from the study (17 patients; 5Æ0%). Between
months 4 and 6 of the study, 7Æ2% discontinued. These with-
drawal rates are comparable with those observed in previously
published extended phase III trials of efalizumab
15,16 and
compare favourably with the withdrawal rate of 28% observed
in a 4-month trial of methotrexate treatment of 44 patients
with psoriasis.
25 The rates of withdrawal continued to be low
and consistent in each 3-month segment of the study, ranging
from 4% to 11Æ4%, except for the 31–33-month segment,
when the rate rose to 25Æ2% due to the study restriction that
patients were ineligible to enter the 34–36-month segment if
efalizumab was available at the time of completion of the 31–
33-month segment. Overall, 18Æ0% of patients withdrew
because of lack of efﬁcacy or worsening of psoriasis.
Efalizumab was generally well tolerated during up to
36 months of continuous treatment. There was no increase
over time in the overall incidence of adverse events, no
increase in common adverse events, no emergence of new
adverse events, no apparent trend towards an increase in the
incidence of clinically signiﬁcant adverse events, and no evi-
dence of cumulative or end-organ toxicity. Clinical trials and
postmarketing reports have infrequently noted new-onset or
worsening arthritis.
26 Arthritis-related adverse events remained
low, ranging between 0Æ4% and 3Æ8% throughout the
36-month study. This corroborates the results of a pooled
analysis of adverse events related to arthropathy from ﬁve
clinical trials of efalizumab in patients with psoriasis.
27
During the study, events of thrombocytopenia were noted
in ﬁve patients; low platelet counts and thrombocytopenia
have been observed in postmarket monitoring.
26 Thus, phys-
icians should follow patients closely for signs and symptoms
of thrombocytopenia with regular assessment of platelet
counts.
Two lymphomas (appearing after 24 and 30 months of
treatment), one melanoma (appearing after 6 months of treat-
ment), 22 cases of NMSC in 11 patients and ﬁve events of
solid tumour (including the one case of melanoma) were
reported during this 36-month study. An increased frequency
of lymphoproliferative diseases
28–30 has been observed among
patients with psoriasis compared with the general population.
In addition, patients with psoriasis appear to be at an in-
creased risk for the development of skin cancers,
31,32 possibly
associated with the prior use of PUVA.
8 Indeed, eight of the
11 patients with NMSC had been treated previously with
phototherapy or reported extensive sun exposure. The rela-
tively small size of the cohort limits the conclusions that can
be drawn regarding rare events such as cancers; however, a
separate analysis of malignancy rates, based on 14 pooled
efalizumab clinical trials, has been performed to address this
question.
33 The incidence rate for solid tumours was
0Æ47⁄100 patient-years in efalizumab-treated patients and
0Æ54⁄100 patient-years in placebo-treated patients, and it ran-
ged between 0Æ26⁄100 and 0Æ44⁄100 patient-years in three
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33 In the 36-month study reported
here, solid tumour events occurred at a rate of 0Æ49⁄100
patient-years. Further analysis of the effect of efalizumab on
malignancy rates will be possible through the Raptiva Epidem-
iologic Study of Psoriasis Outcomes and Safety Events
(RESPONSE), an observational patient registry recording safety
for up to 5 years for efalizumab-treated (n = 5000) and other
biologic-treated (n = 2500) patients. Because patients with
internal malignancies and melanoma were excluded from the
trials, caution should be exercised when considering the use
of efalizumab in patients at high risk for malignancy or with a
history of malignancy.
No evidence of opportunistic infections (e.g. tuberculosis
reactivation), signiﬁcant increase in infections, or neurological
disorders (including multiple sclerosis) was observed in this
long-term study of efalizumab therapy. Congestive heart fail-
ure was noted in a single patient. A postmarketing study is
also being conducted to assess the effect of long-term expos-
ure to efalizumab on the incidence of serious adverse events.
This is the longest study of any biologic therapy for psoria-
sis. Moreover, the use of systemic concomitant medications
for psoriasis-related and nonpsoriasis-related events was
accounted for in this analysis, with efﬁcacy results similar to
those published from an interim analysis
18,19 in which the use
of concomitant medications was not accounted for, thus sug-
gesting that the use of concomitant medications did not
greatly affect efﬁcacy.
Based on the clinical and safety data obtained in this 3-year
clinical study, continuous efalizumab therapy represents an
appropriate treatment for long-term therapy for many patients
with plaque psoriasis.
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